Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind PK, Efficacy and Safety Comparison of CT-P17 vs Humira in Moderate to Severe Chronic Plaque Psoriasis
2022-002336-31Phase 3Completed
- Sponsor
- Celltrion
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in plaque psoriasis and psoriasis (2 arms), sponsored by Celltrion. Primary endpoint: Primary PK endpoints (Week 25-27). Started Aug 2022; status: completed.
02
Drugs
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2022-002336-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002336-31.